20th week of 2012 patent applcation highlights part 53 |
Patent application number | Title | Published |
20120122909 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS - This invention is directed to spiro-oxindole compounds of formula (I): | 2012-05-17 |
20120122910 | METHOD OF TREATING CANCER USING A SURVIVIN INHIBITOR - Disclosed herein are methods of treating cancer by administering to a patient a small molecule inhibitor of Survivin. Also disclosed herein are methods of inhibiting Survivin dimerization in a patient by administering a compound of formula (I), (II), (III), or (IV). Methods of inducing cell cycle arrest in cancer cells, comprising G2/M stage arrest, in a patient by administering a compound of formula (I), (II), (III), or (IV) are also disclosed. Further disclosed herein are methods of inducing apoptosis in cancer cells in a patient by administering a compound of formula (I), (II), (III), or (IV). | 2012-05-17 |
20120122911 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS - The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. | 2012-05-17 |
20120122912 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE - Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis. | 2012-05-17 |
20120122913 | COMBINATION OF CURCUMINOIDS AND MTOR INHIBITORS FOR THE TREATMENT OF TAUOPATHIES - Methods, uses, compositions, combinations and kits relating to the decrease of Tau protein levels, and prevention and/or treatment of diseases or disorders associated with Tau protein (Tauophathies), such as Alzheimer's disease, using a curcuminoid and a mammalian target rapamycin (mTOR) inhibitor, are described. | 2012-05-17 |
20120122914 | Sustained-release composition containing tetrahydropyrido[4,3-b]indole derivatives and preparation of the derivatives - The present invention relates to a sustained-release composition containing 2,3,4,5-tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole or a pharmaceutically acceptable salt thereof as an active ingredient, preparation thereof and the compound. The composition is suitable for oral administration by one time per day, and achieves the peak plasma concentration at 1.0 to 3 hours after oral administration. The composition is suitable for manufacturing a medicament for treatment of cognitive dysfunction syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, or senile dementia. | 2012-05-17 |
20120122915 | CRYSTALLINE FORMS OF PALONOSETRON HYDROCHLORIDE - The present invention provides crystalline forms of Palonosetron hydrochloride, processes for their preparation and pharmaceutical compositions containing such crystalline forms of Palonosetron HCl. | 2012-05-17 |
20120122916 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES - The invention concerns screening molecules with anti-prion activity. More particularly, it concerns kits for screening molecules with anti-prion activity characterized in that they comprise in combination a [PSI+], phenotype yeast, an antibiogram and an agent for purifying prions at sub-efficient doses, said yeast including the ade1-14 allele of the ADE1 gene and an inactivated ERG6 gene, the screening methods, and a family of molecules with anti-prion activity isolated by the inventive screen. The invention is applicable to anti-prion agents for producing medicines in particular for treating neurodegenerative diseases involving protein aggregates. | 2012-05-17 |
20120122917 | Method For Treatment Of HIV And Diseases Of Immune Dysregulation - This invention discloses cannabinoid derivatives and pharmaceutical uses thereof. | 2012-05-17 |
20120122918 | ANTIBACTERIAL AGENTS - Compounds of formula (1) have antibacterial activity: | 2012-05-17 |
20120122919 | PHARMACEUTICAL COMPOSITION COMBINING TENATOPRAZOLE AND A HISTAMINE H2-RECEPTOR ANTAGONIST - The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition, which is intended for the treatment of pathologies linked to gastric hyperacidity, comprises a combination of tenatoprazole and one or more histamine H2-receptor antagonists preferably selected from cimetidine, ranitidine, famotidine and nizatidine. The invention is particularly suitable for the treatment of duodenal and gastric ulcers and the symptoms of, and lesions caused by, gastroesophageal reflux. | 2012-05-17 |
20120122920 | LIBRARIES OF N-SUBSTITUTED-N-PHENYLETHYLSULFONAMIDES FOR DRUG DISCOVERY - New compounds are continually being sought for the treatment and prevention of disorders. The invention relates to N-substituted-N-phenylethylsulfonamides libraries which can be used in the search for, and identification of, new lead compounds that could modulate the functional activity of a biological target. | 2012-05-17 |
20120122921 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - The invention provides a process for the preparation of a compound of Formula 1, | 2012-05-17 |
20120122922 | COMPOSITIONS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE- -3-CARBOXAMIDE - Pharmaceutical compositions including N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods of using such compositions are described herein. | 2012-05-17 |
20120122923 | DUAL MOLECULES CONTAINING A PEROXIDE DERIVATIVE, THEIR SYNTHESIS AND THERAPEUTIC USES - The invention concerns dual molecules corresponding to formula (I): in which: A represents a molecular residue with antimalarial activity of formula (IIa) or (IIIa) or a residue facilitating bioavailability; B represents a cycloalkyl group potentially substituted, or B represents a bi- or tricyclic group capable of being substituted, or B represents 2 cycloalkyl groups linked together through either a single bond or an alkylene chain; m and n represent independently of one another 0, 1 or 2; R | 2012-05-17 |
20120122924 | NAMPT INHIBITORS - Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. | 2012-05-17 |
20120122925 | PERHEXILINE FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY (HCM) - The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of hypertrophic cardiomyopathy, as well as to a method of treating HCM, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said HCM. The invention further relates to a treatment programme for treating HCM, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating HCM or the symptoms thereof. | 2012-05-17 |
20120122926 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of formula I: | 2012-05-17 |
20120122927 | 3 OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS - There are disclosed racemic or enantiomerically enriched 3- or 4-substituted piperidine compounds represented by the following structural formula (I): | 2012-05-17 |
20120122928 | Heteroarylpiperidine and -Piperazine Derivatives as Fungicides - Heteroarylpiperidine and -piperazine derivatives of the formula (I) | 2012-05-17 |
20120122929 | HETEROARYLPIPERIDINE AND -PIPERAZINE DERIVATIVES AS FUNGICIDES - Heteroarylpiperidine and -piperazine derivatives of the formula (I) | 2012-05-17 |
20120122930 | 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents - There are provided compounds of formula (I), wherein R | 2012-05-17 |
20120122931 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - A compound represented by the general formula (I) of the present invention, which has an EP | 2012-05-17 |
20120122932 | Methods and Compositions for Controlling Ectoparasites - A method for inhibiting hatching of an ectoparasite egg, the method comprising exposing the ectoparasite egg to at least one metal chelating agent and/or metalloprotease inhibitor, wherein the metal chelating agent is a compound comprising at least two heteroatoms able to simultaneously coordinate with a metal ion, at least one of the two heteroatoms being selected from nitrogen, sulfur, oxygen and phosphorus, wherein the compound comprises at least one carbocyclic ring substituted with at least one heteroatom and/or with a substituent containing at least one heteroatom, or the compound comprises at least one heterocyclic ring containing at least one heteroatom, wherein said heterocyclic ring is optionally substituted with at least one heteroatom and/or with a substituent containing at least one heteroatom is provided. Methods of treating ectoparasite infestations and compositions for use in such methods are also provided. | 2012-05-17 |
20120122933 | Compounds - The present invention relates to a novel crystalline form of esomeprazole sodium salt. Further, the present invention also relates to the use of the novel crystalline form for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it as well as processes for the preparation of the novel crystalline form. | 2012-05-17 |
20120122934 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES - Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed. | 2012-05-17 |
20120122935 | COMPOSITIONS AND METHODS FOR TREATING NECROTIZING ENTEROCOLITIS - The present invention relates to a method for treating or preventing necrotizing enterocolitis (NEC) in a human neonate in need thereof, comprising administering to the neonate a pharmaceutically effective amount of a composition comprising a poly(ADP-ribose) synthetase/polymerase (PARP) inhibitor. Also contemplated herein is an infant food or treatment composition comprising a PARP inhibitor in an amount that is 5 to 500 times greater than a daily recommended intake dosage for the PARP inhibitor. | 2012-05-17 |
20120122936 | LEAVE-ON NONSOLID SKIN CONDITIONING COMPOSITIONS CONTAINING 12-[(12-HYDROXYOCTADECANOYL)OXY] OCTADECANOIC ACID - Leave-on non-solid skin conditioning compositions containing 12-[(12-hydroxyoctadecanoyl)oxy]octadecanoic acid. 12[(12-hydroxyoctadecanoyl)oxy]octadecanoic acid can be easily incorporated in combination with lipophilic carriers that are liquid at room temperature. Compositions are able to deliver increased energy production by human fibroblasts. Preferred compositions also contain 12-hydroxy stearic acid and thus are able to deliver a wide range of skin benefits. | 2012-05-17 |
20120122937 | METHODS FOR INHIBITING CANCER CELL PROLIFERATION AND INDUCING CANCER CELL APOPTOSIS - Methods and pharmaceutical compositions for treating cancer utilizing compounds characterized by the following structure: | 2012-05-17 |
20120122938 | Alkoxy Compounds for Disease Treatment - The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease. | 2012-05-17 |
20120122939 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS - A new class of alkylsulfonyl-substituted thiazolide compounds is described. These compounds show strong activity against hepatitis virus. | 2012-05-17 |
20120122940 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS - The present disclosure relates to lipid compounds of the general formula (I): | 2012-05-17 |
20120122941 | CYCLOALKYLAMINE DERIVATIVES - Provided is a therapeutic agent for hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like, which has a CaSR activating (agonist) action. A compound represented by the following general formula (1): | 2012-05-17 |
20120122942 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS - The present invention relates to novel pharmaceutically-useful compounds which are antagonists of the 5-oxo-ETE receptors, such as the OXE receptor. These compounds have use as therapeutic and/or prophylactic agents for diseases characterized by tissue eosinophilia, such as inflammatory conditions including respiratory diseases. The invention also relates to pharmaceutical compositions, to the use of such compounds and compositions as medicaments, and to therapeutic methods. | 2012-05-17 |
20120122943 | Melampomagnolide B Derivatives as Antileukemic and Cytotoxic Agents - Melampomagnolide B is disclosed as a new antileukemic sesquiterpene. A biotin-conjugated derivative of melampomagnolide B was prepared to elucidate its mechanism of action. Prodrugs of Melampomagnolide B are disclosed. | 2012-05-17 |
20120122944 | TETRAHYDRONAPHTHALENE DERIVATIVES - This invention relates to novel tetrahydronaphthalene derivatives, and pharmaceutically acceptable salts thereof according to the following formulae, in one embodiment: | 2012-05-17 |
20120122945 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL - The present invention relates to novel compounds, ester pro-drugs of [3-(1-1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals in the treatment of conditions mediated by adrenergic receptors. | 2012-05-17 |
20120122946 | POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME - The invention provides compositions and methods for determining the increased risk for recurrence of certain cancers and the likelihood of successful treatment with one or both of chemotherapy and radiation therapy. The methods comprising determining the type of genomic polymorphism present in a predetermined region of the gene of interest isolated from the subject or patient. Also provided are nucleic acid probes and kits for determining a patient's cancer risk and treatment response. | 2012-05-17 |
20120122947 | SPIRO-OXINDOLE MDM2 ANTAGONISTS - Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases. | 2012-05-17 |
20120122948 | 3-ALKYL-5-FLUOROINDOLE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS - The invention relates to a compound of formula (Ia) | 2012-05-17 |
20120122949 | ULTRA-HIGH STRENGTH INJECTABLE HYDROGEL AND PROCESS FOR PRODUCING THE SAME | 2012-05-17 |
20120122950 | LIBRARIES OF 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES FOR DRUG DISCOVERY - New compounds are continually being sought for the treatment and prevention of disorders. The invention relates to 1-(sulfonyl)-N-phenyl-pyrrolidine 2-carboxamides which can be used in the search for, and identification of, new lead compounds that could modulate the functional activity of a biological target. | 2012-05-17 |
20120122951 | SKIN-WHITENING AGENT AND COSMETIC METHOD FOR WHITENING SKIN - The development of a skin-whitening agent which has a lower molecular weight, can be synthesized through a fewer steps and can be produced at low cost has been demanded. Thus, it is provided by the present invention a skin-whitening agent including one or more compounds selected from the group consisting of 4-cis-hydroxyproline and its derivative and/or its salt, a skin-whitening composition for external formulation to the skin, a cosmetic composition and a pharmaceutical composition, each of which contains the skin-whitening agent of the invention, and a cosmetic method for whitening the skin, which includes a step of administering one or more compounds selected from the group consisting of 4-cis-hydroxyproline and its derivative and/or its salt. In the skin-whitening agent and the cosmetic method for whitening the skin of the invention, the 4-cis-hydroxyproline may be 4-cis-L-hydroxyproline and/or 4-cis-D-hydroxyproline. | 2012-05-17 |
20120122952 | 4-HYDROXYBUTYRIC ACID ANALOGS - This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate. | 2012-05-17 |
20120122953 | METHODS FOR ENHANCING UTROPHIN PRODUCTION VIA INHIBITION OF MICRORNA - This invention provides a method for enhancing utrophin protein production in a cell by inhibiting an utrophin microRNA molecule. Moreover, the invention provides that methods for enhancing utrophin protein production in a muscle cell are used for treating a muscular dystrophy and/or other myopathies. | 2012-05-17 |
20120122954 | Antisense Oligomers Targeting PCSK9 - The present invention relates to oligomer compounds (oligomers), which target PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for the treatment of certain medical disorders, such as hypercholesterolemia and related disorders. | 2012-05-17 |
20120122955 | USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES - The present invention relates to the use of LNA antisense apoB oligonucleotides for the treatment of acute coronary syndrome. | 2012-05-17 |
20120122956 | METHODS FOR INHIBITING ANGIOGENESIS WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN - The present invention relates to methods of inhibiting angiogenesis in mammals. The present invention includes administering polymeric prodrugs of 7-ethyl-10-hydroxycamptothecin to the mammals in need thereof. The present invention also relates to methods of treating a disease associated with angiogenesis in mammals by administering polymeric prodrugs of 7-ethyl-10-hydroxycamptothecin to the mammals in need thereof. | 2012-05-17 |
20120122957 | REGULATION OF AGING BY MODULATION OF MITOCHONDRIAL FUNCTION - The invention relates to the field of longevity enhancement. More particularly, the invention provides compositions and methods relating to modulation of mitochondrial function. In certain embodiments, the invention provides methods and related compositions for the enhancement of longevity in an animal, comprising inhibition of one or more electron transport chain components, such as cco-1 and homologs thereof, in a tissue-specific manner in the animal. | 2012-05-17 |
20120122958 | TRANSCRIPTIONAL REPRESSION LEADING TO PARKINSON'S DISEASE - Parkinson's disease is caused by the preferential loss of substantia nigra dopamine neurons. A Parkin Interacting Substrate, PARIS (ZNF746) is identified. The levels of PARIS are regulated by the ubiquitin proteasome system via binding to and ubiquitination by the E3 ubiquitin ligase, parkin. PARIS is a KRAB and zinc finger protein that accumulates in models of parkin inactivation and in human brain Parkinson's disease patients. PARIS represses the expression of the transcriptional co-activator, PGC-1α and the PGC-1α target gene, NRF-1 by binding to insulin response sequences in the PGC-1α promoter. Conditional knockout of parkin in adult animals leads to progressive loss of dopamine (DA) neurons that is PARIS dependent. Overexpression of PARIS causes selective loss of DA neurons in the substantia nigra, which is reversed by either parkin or PGC-1α co-expression. The identification of PARIS provides a molecular mechanism for neurodegeneration due to parkin inactivation. | 2012-05-17 |
20120122959 | Targeting MicroRNAs for Metabolic Disorders - Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA. | 2012-05-17 |
20120122960 | Organic Compositions to Treat Beta-ENaC-Related Diseases - The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC. | 2012-05-17 |
20120122961 | RNAi Inhibition of Serum Amyloid A For Treatment of Glaucoma - RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression. | 2012-05-17 |
20120122962 | Modified Small Interfering RNA Molecules and Methods of Use - The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering RNAs (siRNAs) using human Dicer. | 2012-05-17 |
20120122963 | LENTIVIRAL TRIPLEX DNA, AND VECTORS AND RECOMBINANT CELLS CONTAINING LENTIVIRAL TRIPLEX DNA - The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo. | 2012-05-17 |
20120122964 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES - Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc. | 2012-05-17 |
20120122965 | COMPOSITIONS FOR SKIN PROTECTION AND IMPROVEMENT OF SKIN DISEASES CONTAINING THE DIBENZO-P-DIOXINE DERIVATIVES - The present invention relates to compositions for skin protection and improvement that contain dibenzo-p-dioxine derivatives as effective components. | 2012-05-17 |
20120122966 | USE OF ORGANIC DYES AS ANALGESIC AGENTS - An organic dye from the group of crystal violet, gentian violet, malachite green oxalate and rhodamine 6G used as an analgesic agent in the form of a solution with the agent dosage ranging from 0.000001 mg to 10 g per intake. It is preferable to take the agent at least two times a day. In particular cases of use the agent is administered by mouth in the form of an aqueous solution before or after meals, or it is administered per rectum in the form of an aqueous solution, or a 1% solution of the agent is administered intravenously, or the agent is used in the form of a 1-5% ointment, or the agent is administered per rectum in the form of suppositories, and when arresting cancer pain the agent is injected into the tumor (under the tumor) or into a metastasis. Herein, one uses as analgesic agents widely available and inexpensive substances that are non-toxic, have no allergic effects and cause no addiction (dependence) when used in pharmaceutically acceptable doses; the treatment time is reduced, treatment efficiency is enhanced, and pain relief is provided while preserving patients' functional activity, using the minimum arsenal of analgesic agents with different effects, and completely eliminating the need for opiates. | 2012-05-17 |
20120122967 | COMPOSITIONS AND PRODUCTS CONTAINING R-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering R-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The R-equol enantiomer can be produced by chiral-phase column separation from a racemic mixture of equol. | 2012-05-17 |
20120122968 | USE OF DYNAMIN RING STABILIZERS - There is provided a method for promoting dynamin ring formation and/or maintenance of dynamin rings in a cell, comprising treating the cell with an effective amount of a dynamin ring stabilizer, or a prodrug or pharmaceutically acceptable salt of the dynamin ring stabilizer. The maintenance or accumulation of dynamin ring formation has particular application in the prophylaxis or treatment of a kidney disease or condition characterized by proteinuria. A dynamin ring stabilizer can be any agent that interacts with dynamin to promote dynamin ring assembly and/or inhibit dynamin ring disassembly. There are also provided methods for prophylaxis or treatment of podocyte dysfunction and/or maintaining or inducing actin cytoskeleton formation in a cell utilizing dynamin ring stabilizers, and for screening a test agent for use as a dynamin ring stabilizer. | 2012-05-17 |
20120122969 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH TOCOTRIENOLS OR TOCOTRIENOL ENRICHED EXTRACTS - Methods of treating or suppressing Pervasive Developmental Disorders (PDDs) including; Autistic Disorder, Asperger's Disorder, Childhood Disintegrative Disorder (CDD), Rett's Disorder, and PDD-Not Otherwise Specified (PDD-NOS) comprising administering to a subject in need thereof a therapeutically effective amount of a tocotrienol, a tocotrienol ester, a tocotrienol ether, a tocotrienol enriched extract or mixtures thereof. | 2012-05-17 |
20120122970 | INSECTICIDAL CARBAMATES EXHIBITING SPECIES-SELECTIVE INHIBITION OF ACETYLCHOLINESTERASE (AChE) - The present invention includes insecticidal carbamates that are useful, for example, for the control of insects, such as mosquitoes, which can be used in applications where exposure to and/or contact with humans is likely. The insecticides of the present invention include phenyl N-methyl carbamates and compositions comprising them that exhibit species-selective inhibition of acetylcholinesterase (AChE) and are preferably toxic to mosquitoes but not humans. Of particular interest are compounds of Formula (I) and Formula (II): | 2012-05-17 |
20120122971 | NEW PROCESS FOR PREPARING HYDROXYLAMINES AND MEDICAMENTS - There is provided a process for the preparation of a compound of formula II, | 2012-05-17 |
20120122972 | NOVEL EICOSANOID DERIVATIVES - The present invention provides compounds (n-3 PUFA derivatives) of formula (I) that modulate conditions associated with cardiac damage, especially cardiac arrhythmias. | 2012-05-17 |
20120122973 | DRY PROCESSING OF RETIGABINE - The invention relates to dry processes for the production of oral dosage forms, especially tablets, containing retigabine and adhesion promoter. In addition, the invention relates to compacted intermediates containing retigabine and an adhesion promoter. Finally, the invention relates to single-dose and multiple-dose containers, preferably sachets and stick-packs, containing the intermediate of the invention. | 2012-05-17 |
20120122974 | HAIR RESTORER - The object of the present invention is to provide a hair restorer which exhibits a stimulatory effect on hair restoration against hair loss, hair thinning, split ends, hair graying, etc., with higher stability and safety than those of known hair restorers containing 5-aminolevulinic acids as active components. By using 5-aminolevulinic acid or its salt or its derivative, and a composition containing iron sodium diethylenetriaminepentaacetate or iron ammonium diethylenetriaminepentaacetate as active components, a hair restorer and a method for restoring hair which are excellent in hair growth promotion, and stability and safety, are provided. | 2012-05-17 |
20120122975 | 4-CYANO-3-BENZOYLAMINO-N-PHENYL-BENZAMIDES FOR USE IN PEST CONTROL - The present invention relates to bis-amide derivatives of formula (I), to processes and intermediates for preparing them, to methods of using them to control insect, acarine, nematode and mollusc pests, and to insecticidal, acaricidal, nematicidal and molluscicidal compositions comprising them. | 2012-05-17 |
20120122976 | PHOSPHATE-FREE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GLAUCOMA - The invention relates to a phosphate-free pharmaceutical composition which comprises at least one FP prostanoid receptor agonist and/or at least one prostamide receptor agonist and also citrate salts and/or citric acid. | 2012-05-17 |
20120122977 | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors - The present invention provides a compound of formula I; | 2012-05-17 |
20120122978 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment - This invention relates to the field of therapeutic agents for the treatment of Age-Associated Memory Impairment (AAMI). In particular, the present invention utilizes compositions comprising at least one compound capable of elevating ketone body concentrations in a mammal (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention of loss of cognitive function caused by reduced neuronal metabolism in AAMI. In one embodiment, the composition includes medium chain triglycerides (MCT). In another embodiment, the compositions are administered in the presence of carbohydrate. The present invention also relates to oral dosage forms, in particular, a nutritional drink comprising at least one compound capable of elevating ketone body concentrations in a mammal. | 2012-05-17 |
20120122979 | CONTROL OF ENZYMATIC PERACID GENERATION - A process is provided for producing target concentrations of peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity under conditions where control of reaction pH by selection of buffer concentration and concentration of perhydrolase and reactants produces a targeted concentration of peroxycarboxylic acids. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided, as are corresponding methods of use. | 2012-05-17 |
20120122980 | METHOD FOR MAKING A PEROXYCARBOXYLIC ACID - The present invention relates to apparatus and methods for making a peroxycarboxylic acid. The apparatus includes a reaction catalyst and a guard column for pretreating one or more reagents, which can increase the life, activity, and/or safety of the reaction catalyst. The peroxycarboxylic acid compositions made by the method and apparatus can include one or more peroxycarboxylic acids. | 2012-05-17 |
20120122981 | Biomarkers Related to Insulin Resistance and Methods using the Same - Biomarkers relating to glucose disposal rate, insulin resistance, and/or insulin resistance-related disorders are provided. Methods based on the same biomarkers are also provided. | 2012-05-17 |
20120122982 | USE OF PUFAS TO TREAT NERVE DAMAGE - The present invention provides use of compounds which are polyunsaturated fatty acid (PUFA) derivatives of formula (I), in the form of racemates, stereoisomers or mixtures of stereoisomers, or pharmaceutically acceptable salts, or solvates thereof, wherein -AIk- is —(CH | 2012-05-17 |
20120122983 | DEODORIZED EDIBLE OIL OR FAT WITH LOW LEVELS OF BOUND MCPD AND PROCESS OF MAKING BY CARBOXYMETHYL CELLULOSE AND/OR RESIN PURIFICATION - A process for making a deodorized edible oil or fat having a low level of bound MCPD (monochloro propanediol esters) and/or low level of bound 3-MCPD is described. The process comprises a step of contacting the oil or fat to a carboxymethyl cellulose or an ion exchange resin. The carboxymethyl cellulose can be a Blanose® cellulose gum and the resin can be a cationic resin. A deodorized vegetable oil or fat and a food product made there from is described. The food product can be an infant formula. It exhibits low levels of bound MCPD and/or low level of bound 3-MCPD. In one embodiment the oil or fat has a reduced level of free fatty acid as well as a limpid aspect and no off-flavors. | 2012-05-17 |
20120122984 | Methods of Treating Lipomas and Liposarcomas - The invention provides methods and compositions for treating lipomas and liposarcomas. The invention also provides methods for reducing white adipose tissue and weight in animals. | 2012-05-17 |
20120122985 | Tranexamic Acid Formulations - Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith. | 2012-05-17 |
20120122986 | Methods of Treating Fragile X Syndrome - Subjects having fragile X syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen, including racemic and R-baclofen. | 2012-05-17 |
20120122987 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) - Compounds are provided having agonistic activity against G protein-coupled receptor 35 (GPR35). The compounds are useful for providing antinociception, providing neuroprotection in case of stroke or ischemia, or treating gastric inflammation. | 2012-05-17 |
20120122988 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS - The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia. | 2012-05-17 |
20120122989 | METHOD OF ENHANCING HAIR GROWTH - Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I | 2012-05-17 |
20120122990 | OLEOYLETHANOLAMIDE BASED FUNCTIONAL MESOPHASES - The present invention relates to the field of liquid crystals. Embodiments of the present invention relate to liquid crystals comprising at least one molecule within N-acyl ethanolamide (NAE) family, for example oleoylethanolamide (OEA), compositions comprising them and their possible uses. | 2012-05-17 |
20120122991 | METHOD FOR TREATING CANCER BY INCREASING AMP-ACTIVATED KINASE ACTIVITY - The invention relates to modulation of LKB1 or AMP kinase protein activity for treating disorders including diabetes and cancer. The invention also relates to screening for agents that modulate the activity of LKB1 or AMP kinase protein, which are useful in the treatment of diabetes and cancer, as well as preparing compounds for treatment of diabetes and cancer. | 2012-05-17 |
20120122992 | SMALL MOLECULE INHIBITORS OF Dusp6 AND USES THEREFOR - Compounds that stimulate fibroblast growth factor production, and thus cell growth are provided. Also provided are compositions comprising the compounds and methods of using the compounds. The compounds can be used to treat wounds, to expand cell populations, such as hematopoietic cells, or to grow tissue in vitro, among other uses. | 2012-05-17 |
20120122993 | PHARMACEUTICAL COMPOSITION CONTAINING 1H-INDEN-1-AMINE, 2,3-DIHYDRO-N-2-PROPYNYL-(1R)-, METHANESULFONATE - A pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of R(+)-N-propargyl-1-aminoindan mesylate thereof, and less than 50% by weight of hexahydric sugar alcohols. | 2012-05-17 |
20120122994 | INSECTICIDAL COMPOUND - An object of the present invention is to provide a new insecticidal compound by paying attention to the insecticidal activity contained in the flower part of marigold, and to provide an insecticide containing the compound as an active ingredient. There are provided an insecticidal compound represented by the following chemical formula: [Formula 1], and an insecticide containing the insecticidal compound as an active ingredient or an insecticide containing, as active ingredients, the insecticidal compound and an insecticidal compound represented by the following chemical formula: [Formula 2], wherein the insecticide can exhibit extraordinary insecticidal efficacy compared with existing pyrethroid-based insecticidal compounds. | 2012-05-17 |
20120122995 | Anti-Inflammatory Agent and Cancer-Preventive Agent Comprising Canolol or Prodrug Thereof and Pharmaceutical, Cosmetic and Food Comprising the Same - An anti-inflammatory agent or cancer-preventive agent comprising 4-vinyl-2,6-dimethoxyphenol of the formula (1): or a PD thereof. | 2012-05-17 |
20120122996 | AZEOTROPE-LIKE COMPOSITIONS COMPRISING 1-CHLORO-3,3,3-TRIFLUOROPROPENE - An azeotrope-like mixture consisting essentially of chlorotrifluoropropene and at least one component selected from the group consisting of a C | 2012-05-17 |
20120122997 | NEW POLYSACCHARIDE-BASED MATERIALS - There is provided a plastic or gel material comprising a mixture of: (a) a compound of formula (I) or a mixture of two or more compounds of formula (I), (R | 2012-05-17 |
20120122998 | Liquid Low Surfactant Compositions Structured with Fibrous Polymer and Specific Low Molecular Weight Water Soluble Polymers Having No Flow Instability or Shear Banding - The invention relates to surfactant structured liquids structured with fibrous polymer and which additionally contain specific low molecular weight water soluble polymers to eliminate flow instability. | 2012-05-17 |
20120122999 | URETHANE AND UREA FLUOROSURFACTANTS - The present invention comprises a compound of a compound of Formula 1 | 2012-05-17 |
20120123000 | FACILITY FOR PRODUCING SYNTHETIC HYDROCARBONS, AND ASSOCIATED METHOD - An assembly for producing at least one synthetic hydrocarbon from at least one inflowing stream of carbon monoxide and one inflowing stream of carbon dioxide is provided. The assembly includes an electrolyzer provided for producing a first stream of hydrogen, a first conversion unit provided for producing an intermediate stream of carbon monoxide from at least one portion of the inflowing stream of carbon dioxide and hydrogen, a reactor for synthesizing said synthetic hydrocarbon; a second conversion unit provided for producing a second stream of hydrogen from carbon monoxide and water, the second hydrogen stream being directed towards the synthesis reactor; a guide assembly provided for selectively distributing the inflowing stream of carbon monoxide between the second conversion unit and the synthesis reactor, and for selectively distributing the first hydrogen stream between the first conversion unit and the synthesis reactor; a control unit provided for controlling the guide assembly. | 2012-05-17 |
20120123001 | PROCESS FOR PRODUCING A MIXTURE OF ALIPHATIC AND AROMATIC HYDROCARBONS - The present invention relates to a process for producing aliphatic and aromatic C2-C6 hydrocarbons by submitting a reformed gas to Fischer-Tropsch synthesis. The reformed gas used in the present process is produced by autothermal dry reforming of a hydrocarbon feed over a Ni/La catalyst and essentially consists of syngas (H | 2012-05-17 |
20120123002 | METHOD FOR PURIFICATION OF ANTIBODY USING POROUS MEMBRANE HAVING AMINO GROUP AND ALKYL GROUP BOTH BOUND TO GRAFT CHAIN IMMOBILIZED ON POROUS SUBSTRATE - A method is disclosed for purifying an antibody monomer, comprising providing a porous membrane comprising a hydrophobic porous substrate, a hydrophilic molecular chain of a different material from that of the porous substrate, immobilized on the surface of pores of the porous substrate, and a side chain of the molecular chain, containing a nitrogen atom to which one to three alkyl groups each having two or three carbon atoms are bonded; passing an antibody solution containing antibody aggregates of dimers or higher-order multimers through the porous membrane to adsorb the antibody aggregates to the porous membrane; and recovering the purified antibody monomer in the passed solution. | 2012-05-17 |
20120123003 | SEALING MATERIAL - A sealing material is provided, which maintains excellent sealing property for a long period of time. The sealing material of the invention is characterized by being prepared by vulcanizing and foaming a mixture containing a rubber component containing a copolymer rubber of ethylene, an α-olefin having 3 or more carbon atoms, and a conjugated diene, a vulcanizing agent, and a blowing agent, wherein the mixture contains a thermoplastic resin having a melting point of 80° C. or less. | 2012-05-17 |
20120123004 | FLAME RETARDED,THEMOPLASTIC COMPOSITION, PROCESS FOR MAKING SAME AND ARTICLE CONTAINING SAME - There is provided herein a composition comprising:
| 2012-05-17 |
20120123005 | NATURAL OIL BASED POLYURETHANE FOAMS - The embodiments of the present invention provide for polyurethane foams that include renewable resources while keeping desired properties of the polyurethane product. For example, described herein, according to embodiments of the invention, are polyurethane foams that have a high concentration of renewable resources while retaining favorable airflow, tensile strength, tear resistance, elongation, indentation force deflection, and/or resilience. These foams may also posses improved yellowing resistance and improved water absorption rates. | 2012-05-17 |
20120123006 | RESIN COMPOSITION FOR CROSSLINKING/FOAM MOLDING, CROSSLINKED MOLDED FOAM, MEMBER FOR FOOTWEAR, AND FOOTWEAR - Disclosed is a resin composition for crosslinking/foam molding which comprises a resin ingredient, a blowing agent, and a crosslinking agent, wherein the resin ingredient is an ethylene/α-olefin copolymer that comprises monomer units based on ethylene and monomer units based on an α-olefin having 3 to 20 carbon atoms and satisfies all of the following: (1) to have a density of 860-950 kg/m | 2012-05-17 |
20120123007 | STYRENIC POLYMER COMPOSITION - There is provided herein a styrenic polymer composition comprising a styrenic polymer and a flame retardant effective amount of a mixture comprising (a) at least one brominated flame retardant; and, (b) at least one solid phosphate ester that has a melting temperature of at least 80 degrees Celsius. | 2012-05-17 |
20120123008 | PROCESS FOR THE PREPARATION OF A POLYURETHANE POLYMER WITH SECONDARY HYDROXYL END GROUPS COMPRISING POLYESTER POLYOLS - The invention relates to a process for the preparation of a polyurethane polymer, comprising the step of reaction of | 2012-05-17 |